Day 1, Thursday, May 11th | |
08:30-10:00 | ADCs: a new era in myeloma therapy Pre-COMy Springer Healthcare IME CME Symposium supported by GSK |
10:00-10:30 | Coffee Break |
10:30-10:45 | COMy 2023 kick-off |
10:45-12:15 | Session 1: Latest updates in disease biology |
12:15-13:00 | Lunch Break |
13:00-14:00 | BCMA-Targeted Therapies – A New Combination Partner in Early Relapsed/Refractory Multiple Myeloma Industry-supported Symposium by GSK |
14:00-14:15 | Technical Break |
14:15-15:45 | Session 2: Disease work-up and risk assessment |
15:45-17:15 | Session 3: Precursor conditions and related disorders – diagnosis and management |
17:15-17:45 | Coffee Break |
17:45-19:15 | Clinical utility of NGS-MRD in multiple myeloma Industry-supported Symposium by Adaptive Biotechnologies |
19:15-19:30 | Technical Break |
19:30-20:15 | Session 4: Plenary lecture |
Day 2, Friday, May 12th | |
08:00-08:30 | Good Morning Breakfast |
08:30-09:30 | Let’s get real: Modern management of RRMM in older patients Medthority CME Symposium supported by Takeda |
09:30-09:40 | Technical Break |
09:40-10:10 | The evolving role of alkylating agents in multiple myeloma; from the past and present to next generation peptide drug conjugates Industry-supported Presentation by Oncopeptides |
10:10-11:25 | Session 5: IMS: Impact on real life |
11:25-11:50 | Coffee Break |
11:50-13:20 | Session 6: Practical considerations in the management of myeloma |
13:20-14:00 | Lunch Break |
14:00-15:00 | We need a little controversy: fresh perspectives on cure in MM Industry-supported Symposium by Janssen |
15:00-15:15 | Technical Break |
15:15-16:30 | Session 7: Treatment of relapsed myeloma – past, present and future |
16:30-17:00 | Coffee Break |
17:00-18:00 | Immunotherapy in multiple myeloma (MM): update on evolving use and therapy management Industry-supported Symposium by Pfizer |
18:00-18:15 | Technical Break |
18:15-19:15 | Session 8: Plenary session I |
19:15-20:00 | Award Ceremony |
Day 3, Saturday, May 13th | |
07:45-08:00 | Good Morning Breakfast |
08:00-09:00 | Prediction of response to T-cell engagers CME Symposium by a Pfizer educational grant |
09:00-09:10 | Technical Break |
09:10-09:55 | XPO-1 inhibitors in myeloma: where do we stand? Industry-supported Symposium by Menarini-Stemline |
09:55-11:25 | Session 9: How I treat a frail myeloma |
11:25-11:45 | Coffee Break |
11:45-12:45 | Reform or Revolution? Modern Insights in MRD Industry-supported Symposium by Sanofi |
12:45-13:30 | Lunch Break |
13:30-15:00 | Session 10: How I treat a young and fit myeloma patient |
15:00-16:30 | Session 11: How I treat a relapsed/refractory myeloma |
16:30-16:45 | Coffee Break |
16:45-18:00 | Treatment options in RRMM: expert controversies Industry-supported Symposium by BMS |
18:00-18:15 | Technical Break |
18:15-19:15 | Session 12: Plenary session II |
19:15-19:30 | In-Person Conclusions |
ONLINE Day 4, Sunday, May 14th | |
09:00-10:20 | Session 13: Abstract communications I |
10:20-11:20 | Immunotherapy and bispecifics: a real-life case discussion Virtual CME Symposium by a Pfizer educational grant |
11:20-12:40 | Session 14: Abstract communications II |
12:40-13:10 | From conventional alkylating agents to peptide-drug conjugates Virtual CME Symposium by Oncopeptides |
13:10-14:00 | Final Panel Discussion: Immunotherapy for multiple myeloma: where to go from here? |
Industry TimetableAdam Barkay2023-05-12T12:55:19+00:00